P atients with chronic inflammatory autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus (SLE), have an increased risk of developing cardiovascular disease. Particularly, atherosclerosis and the risk of myocardial infarction are raised in these patients. Systemic inflammation is considered to be one of the main underlying mechanisms of the increased risk, but studies identifying the culprit molecules at play are still evolving. 1
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In 2003, several groups identified a typical type I interferon (IFN) signature profile in the peripheral blood of patients with SLE, which was further substantiated later by enhanced expression of IFN-dependent genes in the synovial tissue of patients with SLE. 2 These studies prompted the field to initiate investigations into the role of type I IFNs in SLE disease progression and associated comorbidities. The IFN signature clearly associates with disease in a large proportion of the patients and is nowadays considered an attractive target for therapeutic interventions. 2 Several clinical trials targeting the type I IFN pathway have been initiated using either monoclonal antibody approaches or active immunization against IFN-α. A phase II trial using an antibody against the type I IFN receptor recently showed that it can accomplish suppression of the IFN profile and reduce disease activity in patients. 3 Type I IFNs were discovered >50 years ago and initially mainly implicated in antiviral responses. 4 Nowadays, it is clear that they not only serve in host protection but also have a major function in immune regulation and pathology of disease. Several studies have focused on the effects of type I IFNs on atherosclerosis development. 5 Mouse models for SLE were shown to have increased atherosclerosis, 6 and type I IFNs cause endothelial dysfunction in relation to atherosclerotic disease. 7 Moreover, it was recently shown in mice that type I IFNs promote the expression of chemotactic receptors and ligands (CCR5 [CC chemokine receptor] and CCL5 [CC chemokine ligand]) and thereby promote monocyte vessel wall interactions, recruitment of cells to atherosclerotic lesions, and hence promote atherogenesis. In human atherosclerotic lesions, characteristics of plaque instability associated with an IFN signature profile. 8 In their current study, Diao et al 9 now show that type I IFNs affect the functioning of smooth muscle progenitor cells (SMPCs) and hereby may affect atherosclerosis development. In their studies, they performed in vitro SMPC colony-forming assays using peripheral blood mononuclear cells from mice and show that type I IFNs promote SMPC colony formation. This effect was directly mediated by type I IFN receptordependent signaling as peripheral blood mononuclear cells from type I IFN receptor-deficient mice did not show this increase in SMPC colony formation in response to the type I IFN. SMC marker analyses indicated that type I IFN inhibited full maturation of SMCs and keeps SMCs in a more immature state on differentiation. Subsequently, they switched to in vivo models. They took an elegant approach of overexpressing IFNa5 systemically by electroporation of an expression plasmid in the calf muscle of mice. Again they could show that elevated systemic levels of type I IFN led to increased SMPC colony numbers when culturing peripheral blood mononuclear cells from these animals. They could also show that the animals expressing type I IFN showed intimal thickening, and these preatherosclerotic-like lesions were mainly composed of layers of SMCs. Colocalization studies showed that lesional SMCs in type I IFN expressing animals had a more immature phenotype characterized by the lower or lack of expression of smooth muscle myosin heavy chain, similar as was observed in vitro.
The exact role of SMPCs in atherosclerosis still needs further elucidation. There is a controversy about whether they originate from circulating cells or from local tissue precursors. 10, 11 In addition, a further step needs to be taken into how they affect atherosclerotic plaque development. One mouse study showed that mobilization of SMPCs promoted atherosclerotic plaque development and led to larger lesions. 12 An alternative approach studying CXCL12 actually identified that recruitment of SMPCs led to stabilization of lesions without affecting total lesion size, thus leading to a beneficial phenotype. 13 These current data indicate that in SLE patients, early atherosclerosis may be promoted by type I IFNs by mobilization of SMPCs and by keeping them in an immature state. The functional consequences of the generation of these immature SMCs still require more studies. It will be of great interest to analyze how these SMPC-derived immature SMCs behave in further and more advanced atherosclerosis development and particularly how they respond to hyperlipidemic conditions, keeping in mind that type I IFNs promote foam cell formation of macrophages by influencing influx and efflux pathways. 14 SMCs may adopt a macrophage-like foam cell phenotype, and immature SMCs may more easily switch to such a phenotype and thus contribute substantially to plaque growth. Recent studies show that in human advanced atherosclerotic plaques, a large proportion of the foam cells that are positive for the macrophage marker CD68 also expresses smooth muscle cell
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February 2016 α-actin. 15 Moreover, Shankman et al 16 recently performed elegant SMC lineage tracing studies in mice and showed that SMCs in atherosclerotic plaques lose their classical markers and adopt phenotypic characteristics of other cell types, including macrophage-like foam cells. How IFNs act on these processes remains to be elucidated. It is tempting to speculate that by dampening full SMC differentiation from SMPCs, type I IFNs, in addition to their already demonstrated atherosclerosis promoting effects on other cell types, may be further promoting progression of disease. The ongoing type I IFN interventions to treat SLE are thus also of great interest for SLE-associated cardiovascular disease. They will greatly aid in gaining more insight into how inflammatory pathways contribute to the pathogenesis of atherosclerosis.
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Figure.
Elevated levels of type I interferon (IFN) in patients with systemic lupus erythematosus may prevent full maturation of smooth muscle cells (SMC) from smooth muscle progenitor cells (SMPC) and thereby induce a cellular state that contributes to intimal thickening and that may be more prone to develop into macrophage-like foam cells.
